CELC

Celcuity Inc.

Fundamental data last updated:October 30, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

11/11/2026

Business Summary

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

 


Analyze CELC on TradingView

VALUATION

P/E

-15.34

Market Cap ($M USD)

$3.22B

Forward P/E

10.79

PEG

-0.46

PRICE TO SALES

0.00

PRICE TO BOOK

-282.21

EV / EBITDA

-20.47

5-Year Average P/E

Free Cash Flow Yield

-5.97%

DCF Value

$-0.68

Graham Number

N/A

Price to FCF

-16.76

EV to FCF

-19.73

Earnings Yield

-6.28%

FCF Yield

-5.97%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$4.13

Next Year EPS Growth Estimate

-$5.14

Next Year Revenue Growth Estimate

$23.34M

Return on Equity (ROE)

-350.78%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

-59.02

Piotroski F-Score

2

Altman Z-Score

1.56

Return on Invested Capital (ROIC)

-28.14%

Current Ratio

8.93

Quick Ratio

8.93

Net Debt to EBITDA

-3.09

Interest Coverage

-5.95

Gross Profit margin

0.00%

FCF PER SHARE

$-3.51

REVENUE PER SHARE

$0.00

Analyze CELC on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Celcuity Inc. significantly. With a Forward P/E of 11.43, the stock appears undervalued relative to its future earnings potential, especially when juxtaposed against a staggering negative DCF Value. The Altman Z-score of 10.40 suggests robust financial health, indicating low bankruptcy risk. However, the negative Earnings Yield and a Price/Book ratio of 68.48 raise red flags about current valuation excesses. This is a complex narrative of potential growth overshadowed by present inefficiencies.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Celcuity is poised to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology positions it well for adaptation. However, execution will be key in translating tech potential into tangible results.

The Bull Case

For the GARP investor, Celcuity offers a compelling narrative of future growth. The Forward PEG ratio of 0.03 is a beacon of undervaluation, suggesting the market is underestimating its growth trajectory. Despite a low Piotroski F-Score of 2, the high Altman Z-score and substantial sales growth forecast indicate strong institutional support. The company’s high Current Ratio of 10.55 reflects liquidity strength, providing a cushion for strategic investments.

The Bear Case

Yet, the bear case is hard to ignore. Celcuity's astronomical Price/Book ratio and negative EV to EBITDA signal potential overvaluation and operational inefficiencies. The negative ROIC and FCF Yield highlight a troubling inability to generate returns from invested capital. Trading near its 52-week high, the stock appears technically overextended, suggesting caution for momentum investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$157.67

Institutional Ownership %

1-Year Beta

0.16

Insider Buying % (6 Mo)

Distance to 52-Week High

129.51%

Distance to 52-Week Low

18.63%

EARNINGS SURPRISE %

-24.14%

50-DAY SMA

$80.07

200-DAY SMA

$101.60

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.